NCT03109379 - Safety and Tolerability of TAR-302-5018 in Subjects With Idiopathic Overactive Bladder | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

April 4, 2017

Primary Completion Date

September 27, 2019

Study Completion Date

September 27, 2019

Conditions

Idiopathic Overactive Bladder With Urinary Incontinence

Interventions

DRUG

Trospium-Releasing Intravesical System (TAR-302-5018)

TAR-302-5018 is a passive, nonresorbable trospium-releasing intravesical system whose primary mode of action is the controlled release of trospium into the bladder over a 42-day period.

Trial Locations (12)

10016

Manhattan Medical Resear, New York

23462

Urology of Virginia, Virginia Beach

27103

UWCR - Lyndhurst Gynecologic Associates, Winston-Salem

33060

Clinical Research Center of Florida, Pompano Beach

48073

William Beaumont Hospital - Royal Oak, Royal Oak

48084

Michigan Institute of Urology, Troy

70115

DelRicht Clinical Research, LLC, New Orleans

85715

Urological Associates of Southern Arizona, Tucson

92108

Medical Center for Clinical Research, San Diego

02472

Bay State Clinical Trials, Inc, Watertown

08043

New Jersey Urology, Voorhees Township

11530-1664

Accumed Research, Garden City

All Listed Sponsors

lead

Taris Biomedical LLC

INDUSTRY